The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs...read more
Kinnate Biopharma, a preclinical biotech developing targeted kinase inhibitors for difficult-to-treat cancers, raised $240 million by offering 12 million shares at $20, above the range of $18 to $19. The company offered 0.5 million more shares than anticipated....read more
Kinnate Biopharma, a preclinical biotech developing targeted kinase inhibitors for difficult-to-treat cancers, raised the proposed deal size for its upcoming IPO on Wednesday. The San Diego, CA-based company now plans to raise $213 million by offering 11.5...read more
Kinnate Biopharma, an early stage biotech developing small molecule kinase inhibitors for difficult-to-treat cancers, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $170 million by offering 10 million shares at a price...read more
US IPO Weekly Recap: The IPO market is taught a thing or two in an 8 IPO week
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs...read more
Oncology biotech Kinnate Biopharma prices further upsized IPO at $20, above the upwardly revised range
Kinnate Biopharma, a preclinical biotech developing targeted kinase inhibitors for difficult-to-treat cancers, raised $240 million by offering 12 million shares at $20, above the range of $18 to $19. The company offered 0.5 million more shares than anticipated....read more
Oncology biotech Kinnate Biopharma ups proposed deal size by 25% ahead of $213 million IPO
Kinnate Biopharma, a preclinical biotech developing targeted kinase inhibitors for difficult-to-treat cancers, raised the proposed deal size for its upcoming IPO on Wednesday. The San Diego, CA-based company now plans to raise $213 million by offering 11.5...read more
Oncology biotech Kinnate Biopharma sets terms for $170 million IPO
Kinnate Biopharma, an early stage biotech developing small molecule kinase inhibitors for difficult-to-treat cancers, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $170 million by offering 10 million shares at a price...read more